Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis with Boric Acid
For fluconazole-resistant vulvovaginal candidiasis, use intravaginal boric acid 600 mg suppositories daily for 14 days as the primary treatment, with consideration for maintenance therapy twice weekly thereafter to prevent recurrence.
Initial Treatment Regimen
The standard acute treatment protocol is:
- Boric acid 600 mg vaginal suppositories
- Daily administration for 14 days 1, 2
- No advantage has been demonstrated for extending therapy beyond 14-21 days for initial treatment 2
This regimen achieves mycological cure rates of 64-72% in fluconazole-resistant cases 3, 1. In the most recent study from a tertiary vulvovaginal health center, boric acid demonstrated an 85.7% mycological cure rate and 73.7% clinical cure rate specifically in fluconazole-resistant Candida albicans infections 3.
Species-Specific Considerations
Boric acid is particularly valuable for non-albicans species, especially C. glabrata, which has intrinsic azole resistance. In diabetic women with C. glabrata VVC, boric acid achieved significantly higher mycological cure (72.4%) compared to fluconazole (33.3%) 1. The drug works across multiple Candida species and morphologies, including preventing hyphal formation and disrupting mature biofilms—mechanisms that fluconazole cannot achieve 4.
Maintenance Therapy
Critical caveat: Recurrence is common without maintenance therapy. After successful initial treatment, 14.3% of patients experienced mycological recurrence within 3 months 3, and only 46.6% of diabetic women remained cured at 3 months 5.
For maintenance:
- Boric acid 600 mg suppositories twice weekly is the most commonly utilized regimen 6
- Begin maintenance after completing the initial 14-day course and confirming negative cultures
- Continue indefinitely for recurrent vulvovaginal candidiasis (≥3 episodes per year)
Pregnancy Contraindication
Boric acid must be avoided during pregnancy 6. This is an absolute contraindication—alternative agents must be used in pregnant women.
Second-Line Option
If boric acid fails, topical flucytosine cream nightly for 14 days achieves 90% success in azole-refractory cases 2. This is reserved for patients who have failed both boric acid and azole therapy.
Common Pitfall
The most significant error in clinical practice is inadequate treatment duration. A recent survey found only 2.9% of patients used boric acid for the guideline-recommended duration of >21 days (including maintenance) 7. Short courses lead to predictable treatment failure and recurrence. Patients require explicit counseling that the initial 14-day course must be completed, followed by ongoing maintenance therapy.
Safety Profile
Local side effects are uncommon with boric acid 2. The regimen is well-tolerated and cost-effective, though patients should be counseled about the need for consistent adherence to both acute and maintenance phases.